Evidence map›Paper›PMID 33795809›Full record

ArticleBritish journal of cancer2021

CD8

Robiya Joseph, Rama Soundararajan, Suhas Vasaikar, Fei Yang, Kendra L Allton, Lin Tian, Petra den Hollander, Sevinj Isgandarova, Monika Haemmerle, Barbara Mino and 17 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Robiya JosephDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rama Soundararajan *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Suhas Vasaikar *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fei YangDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kendra L AlltonDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin TianDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Petra den HollanderDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sevinj IsgandarovaInstitute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, USA.
Monika HaemmerleDepartment of Gynecologic Oncology and Reproductive Medicine and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Barbara MinoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tieling ZhouDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Crystal ShinDepartment of Surgery, Baylor College of Medicine, Houston, TX, USA.
Melisa Martinez-PaniaguaDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Aysegul A SahinDepartment of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jaime Rodriguez-CanalesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Juri GelovaniDepartment of Experimental Diagnostic Imaging, Wayne State University, Detroit, MI, USA.
Jeffrey T ChangDepartment of Integrative Biology and Pharmacology, UT Health Sciences Center at Houston, Houston, TX, USA.
Ghanashyam AcharyaDepartment of Surgery, Baylor College of Medicine, Houston, TX, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Don L GibbonsDepartment of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2362-3094
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle C BartonDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Navin VaradarajanDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA.
Jeffrey M RosenDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Xiang H ZhangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Sendurai A ManiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. smani@mdanderson.org.ORCID http://orcid.org/0000-0002-5918-4276
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Houston · USTexas A&M Health Science Center · USThe University of Texas Health Science Center at Houston · USWayne State University · US

Funding

Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progressionR01CA155243 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MANI, SENDURAI AYYAVOO · 2011 to 2022
$3.2M
NCI NIH HHS R01 CA155243
6 · The paper itself

Abstract

backgroundThe mechanism by which immune cells regulate metastasis is unclear. Understanding the role of immune cells in metastasis will guide the development of treatments improving patient survival.

methodsWe used syngeneic orthotopic mouse tumour models (wild-type, NOD/scid and Nude), employed knockout (CD8 and CD4) models and administered CXCL4. Tumours and lungs were analysed for cancer cells by bioluminescence, and circulating tumour cells were isolated from blood. Immunohistochemistry on the mouse tumours was performed to confirm cell type, and on a tissue microarray with 180 TNBCs for human relevance. TCGA data from over 10,000 patients were analysed as well.

resultsWe reveal that intratumoral immune infiltration differs between metastatic and non-metastatic tumours. The non-metastatic tumours harbour high levels of CD8

conclusionsCD8

Indexed as

AnimalsBreast NeoplasmsCD4 AntigensCD8 AntigensCD8-Positive T-LymphocytesCell Line, TumorFemaleGene Knockout TechniquesHumansLung NeoplasmsMiceMice, Inbred NODMice, NudeMyeloid-Derived Suppressor CellsNeoplastic Cells, CirculatingPlatelet Factor 4CD4 AntigensCD8 AntigensPF4 protein, humanPlatelet Factor 4

Identifiers

PMID33795809
PMCPMC8292398
OpenAlexW3142673705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.